文献速递中医内科中药与中成药合理使用

藁本内酯靶向S100A9抑制中性粒细胞活化减轻心肌梗死

Ligustilide alleviates myocardial infarction by targeting S100A9 to inhibit neutrophil activation and attenuate the inflammatory cascade.
PubMed 文献 · J Ethnopharmacol · 2026-05-18

该研究探讨速效救心丸主要活性成分藁本内酯(Lig)靶向S100A9抑制中性粒细胞活化、减轻心肌梗死(MI)炎症损伤的分子机制。通过生物信息学、分子对接及小鼠MI和缺血再灌注模型验证,Lig可下调S100A9,减少中性粒细胞/单核细胞浸润、NET形成及NLRP3炎症小体活化,缩小梗死面积并改善心功能。

要点

  • 藁本内酯是速效救心丸靶向S100A9的主要活性成分。
  • Lig抑制中性粒细胞活化、NET形成及NLRP3炎症小体。
  • Lig减轻MI后炎症、凋亡,缩小梗死并改善心功能。

核心结论

  • 藁本内酯通过靶向S100A9抑制中性粒细胞活化,减轻心肌梗死后急性炎症损伤并发挥心脏保护作用。

研究设计与样本

  • 研究结合生物信息学分析人MI数据集与小鼠MI模型验证,并采用分子对接、SPR、MD模拟和CETSA筛选SJP中靶向S100A9的成分。
  • 在MI模型中通过qRT-PCR、Western blot和ELISA定量S100A9表达,超声心动图、TTC染色、酶学和组织病理学评估心功能。
  • 采用流式细胞术评估心肌中性粒细胞/单核细胞浸润及中性粒细胞S100A9表达,并用缺血再灌注(I/R)模型进一步验证。

主要发现

  • S100A9是介导速效救心丸心脏保护的关键靶点,藁本内酯为其特异性配体。
  • MI后Lig下调S100A9,减轻炎症和凋亡,缩小梗死面积并改善心功能。
  • Lig抑制心肌中性粒细胞/单核细胞浸润、NET形成和NLRP3炎症小体活化,降低心脏TNF-α/IL-1β及血清IL-1β水平。
  • Lig减少骨髓和脾脏炎症细胞比例,增加骨髓Lin-和LSK细胞,降低巨核-红系祖细胞比例,下调粒细胞增殖/分化相关mRNA。
  • 在I/R模型中Lig通过靶向S100A9发挥一致的心脏保护作用。

临床怎么用

  • 从机制层面支持速效救心丸及其活性成分藁本内酯用于心肌梗死早期炎症损伤的干预。
  • 提示S100A9可作为MI抗炎治疗的潜在靶点,藁本内酯是其特异性配体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Suxiao Jiuxin Pills (SJP), as a classic Chinese patent medicine formula, is clinically used to treat angina pectoris and myocardial ischemia (MI). However, its pharmacodynamic basis and potential molecular mechanisms remain incompletely elucidated. Bioinformatics analysis identified S100A9 as a key MI target, and ligustilide (Lig) (primary active component of SJP) as its specific ligand. AIM OF THE STUDY: This study aims to elucidate the molecular mechanism by which Lig targets S100A9 to inhibit neutrophil activation and alleviate MI. MATERIALS AND METHODS: Bioinformatics analysis of human MI datasets and murine MI model validation identified S100A9 as SJP's potential target for alleviating early post-MI inflammatory injury. Molecular docking, SPR, MD simulations, and CETSA were used toscreened SJP's S100A9-targeting components. In MI models, S100A9 expression (infarcted myocardium/peripheral blood) was quantified by qRT-PCR, Western blot, and ELISA. Cardiac function was evaluated by echocardiography, TTC staining, enzymatic and histopathological assays. Flow cytometry assessed post-MI myocardial neutrophil/monocyte infiltration and neutrophil S100A9 expression. NET formation and NLRP3 inflammasome-associated molecules expression were assessed by Western blot and qRT-PCR, respectively. The mRNA expression of inflammatory cytokines was analyzed by qRT-PCR. Serum IL-1β levels were quantified by ELISA. Flow cytometry analyzed bone marrow (BM)/spleen neutrophil/monocyte infiltration and BM cell subset proportions. qRT-PCR determined mRNA levels of BM proliferation- and differentiation-related factors. An ischemia-reperfusion (I/R) model further confirmed the cardioprotective effect of Lig targeting S100A9 to inhibit neutrophil activation. RESULTS: S100A9 was the key target mediating SJP's cardioprotection, with its major bioactive component Lig as a specific S100A9 ligand. Post-MI, Lig downregulated S100A9, attenuated inflammation and apoptosis, reduced infarct size, and improved cardiac function. It suppressed myocardial neutrophil/monocyte infiltration, NET formation, and NLRP3 inflammasome activation, and decreased cardiac TNF-α/IL-1β and serum IL-1β levels. Furthermore, it reduced inflammatory cell proportions in BM and spleen, increased BM Lin- and LSK cells, decreased megakaryocyte-erythroid progenitor ratios, and downregulated granulocyte proliferation/differentiation-related mRNA. In the I/R model, Lig exerted consistent cardioprotection via targeting S100A9. CONCLUSION: Lig, the principal bioactive component of SJP, confers cardioprotection by targeting S100A9 to inhibit neutrophil activation and attenuate acute myocardial inflammatory injury post-MI.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Guo Y, Li M, Fang Z, et al. Ligustilide alleviates myocardial infarction by targeting S100A9 to inhibit neutrophil activation and attenuate the inflammatory cascade. J Ethnopharmacol. 2026. PMID: 42155822. doi:10.1016/j.jep.2026.121883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。